Brief: Lisata Therapeutics- Will Evaluate Efficacy Of Certepetide
15/04/2025 14:23
April 15 (Reuters) - Lisata Therapeutics Inc LSTA.O: LISATA THERAPEUTICS- WILL EVALUATE EFFICACY OF CERTEPETIDE, AS PAYLOAD IN CONTEXT OF CATALENT'S SMARTAG ADC DUAL-PAYLOAD TECHNOLOGY PLATFORM Source text: ID:nGNX3LQqDg Further company coverage: LSTA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Lisata Therapeutics
See all newsBrief: Lisata Therapeutics - Amends Merger Offer Price To $4 Per Share Plus CVR
Brief: Lisata Therapeutics Enters Into Definitive Agreement To Be Acquired By Kuva Labs, Inc.
U.S. STOCKS ON THE MOVE-Oklo, AMD, Lam Research
U.S. STOCKS ON THE MOVE-Aligos, Intel, Travelers Companies
Lisata jumps as Kuva Labs strikes acquisition deal